9th Annual Biomarkers Congress
Duke Debates: Controversies in the Management of Patients With Hematologic Malignancies
The Grove Park Inn
290 Macon Ave.
Asheville, North Carolina 28804
http://www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/652
   Speakers
   --------

   Joseph Moore,
   David Rizzieri

   This activity is presented by Physicians’ Education Resource in
   conjunction with Duke University Division of Cellular Therapy and Duke
   Oncology Network.

   The Duke Debates: Controversies in the Management of Patients With
   Hematologic Malignancies symposium provides a unique opportunity for
   medical oncologists, hematologists, physician assistants, nurse
   practitioners, nurses, and other health care professionals to obtain
   practical updates and expert views on management of and controversies
   in hematologic malignancies in order to increase knowledge and apply
   new data to practice. Topics include: Simultaneous sessions in acute
   myeloid leukemia Therapy of elderly patients, timing of transplant,
   and cognitive changes from therapy Insights into classification,
   diagnosis, and prognosis Debates on current issues Role of active
   therapy in secondary leukemia Splenectomy versus thrombopoietic agents
   in immune thrombocytopenic purpura First- versus second-generation
   tyrosine kinase inhibitors as induction therapy for chronic myeloid
   leukemia New induction regimens for indolent non-Hodgkin lymphoma Role
   of maintenance therapy following transplant in multiple myeloma


   290 Macon Ave., Asheville, NC, 28804 , United States

   Loading (May not complete on browsers without Javascript support)...

   Try again

Schedule of Presentations:

Friday, April 29, 2011
12:30:00 Registration
12:50:00 Simultaneous Session 1 | Advanced Practice Nursing and Pharmacy | Acute Myeloid Leukemias Case Study and NCCN Guidelines™ Review Jennifer Loftis
12:55:00 Session 1 | Welcome and Introductions Jennifer Loftis
13:00:00 Session 1 | Disease Overview and Diagnostic Testing Heather Brumbaugh
13:45:00 Session 1 | Transplantation Options Martha Lassiter
14:00:00 Simultaneous Session 2 | Practical Hematopathology | Cells, Chromosomes, and Molecules in AML—Providing Insights Into Classification, Diagnosis, and Prognosis Patrick Buckley
14:05:00 SESSION 2 | Welcome and Introductions Patrick Buckley
14:10:00 SESSION 2 | Current Classification of Acute Myeloid Leukemia | Implications of Dysplastic Changes and Cytogenetic and Molecular Abnormalities Patrick Buckley
14:15:00 Session 1 | Treatment of Refractory | Relapsed Disease Donna Adams
14:40:00 SESSION 2 | Determining Immunophenotype in Acute Myeloid Leukemia | At Diagnosis and Beyond Anand Shreeram Lagoo
14:45:00 Session 1 | Break
15:00:00 Session 1 | Management of Diabetes in the Oncology Patient Angela Johns
15:10:00 SESSION 2 | Recurrent Cytogenetic Abnormalities | Diagnostic and Prognostic Implications Catherine Rehder
15:40:00 SESSION 2 | Recurrent Molecular Mutations in Acute Myeloid Leukemia Michael B. Datto
15:45:00 Session 1 | Cognitive Changes After Chemotherapy Krista Rowe
16:10:00 SESSION 2 | Case Studies in Acute Myeloid Leukemia | An Integrated Approach to Diagnosis
16:15:00 Session 1 | Caring for the Elderly Oncology Patient
16:45:00 Session 1 | Adjourn
16:45:00 SESSION 2 | Adjourn
17:00:00 SESSION 2 | Reception
17:00:00 Session 1 | Reception
Saturday, April 30, 2011
07:30:00 Registration and Continental Breakfast
07:55:00 Leukemia Session Joseph Moore
08:00:00 Welcome and Presession Survey Joseph Moore
08:10:00 Debate | Options for chronic myeloid leukemia induction therapy | the choice for a new generation? Joseph Moore
09:00:00 Debate | Induction therapy for patients with acute lymphoblastic leukemia should contain asparaginase. Mitchell Horwitz, Dan Douer
09:45:00 Break
10:00:00 Personalizing Health Care Through Genomic Profiling Sandeep S. Dave
10:45:00 Debate | Therapy for secondary leukemia in the “robust” elderly patient Anthony N. Galanos , Arati Rao
11:30:00 Lunch
12:25:00 Hematology Thomas L. Ortel
12:30:00 Debate | Splenectomy vs. thrombopoietic agents for immune thrombocytopenic purpura | What’s the right sequence of options?
13:10:00 Debate Pharmacomechanical vs. medical treatment of extensive deep vein thrombosis Thomas L. Ortel , Michael J. Miller
13:50:00 Use of Complement Inhibitors in the Treatment of Complement Activating Diseases
14:20:00 Debate | Anticoagulant therapy | We’re ready to move beyond warfarin.
14:45:00 Postsession Survey and Question-and-Answer Session
15:00:00 Adjourn
Sunday, May 1, 2011
07:30:00 Registration and Continental Breakfast
07:55:00 Lymphoma Session Anne W. Beaven
08:00:00 Welcome and Presession Survey Anne W. Beaven
08:10:00 Debate | Bendamustine | rituximab is the standard of care for induction therapy of follicular lymphoma. Anne W. Beaven, Nam H. Dang
09:00:00 The Future of Chronic Lymphocytic Leukemia Therapy Mark C. Lanasa
09:45:00 Break
09:55:00 Novel Agents in Chronic Lymphocytic Leukemia
10:30:00 Debate | Maintenance vs. no maintenance after autologous transplantation for myeloma
11:15:00 New Options in Hodgkin Lymphoma Anne W. Beaven
11:45:00 Case-Based Tumor Board Discussion | All That’s Clonal Is Not Cancer Jon Gockerman
12:25:00 Postsession Survey and Question-and-Answer Session
12:30:00 Adjourn
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.